RedDress develops personalized and autologous wound management solutions derived from patients' own blood, marketed under its ActiGraft product suite. ActiGraft systems treat a wide variety of chronic and acute wounds, including diabetic and neuropathic ulcers, venous ulcers, pressure injuries, traumatic and post-surgical wounds, skin tears and more. The company received FDA clearance and a CE Mark in 2020; its systems are available in 40 countries across five continents and have helped over 6,000 patients. RedDress is led by CEO Alon Kushnir and operates a U.S. subsidiary, RedDress Inc., in Jacksonville, Florida. The company plans to use the new funding to support increased adoption of its product suite, establish global partnerships, and expand its proprietary blood-based technology. The recent Series D also brought the company's total known funding to $43M.

Total raised

$26M

Funding rounds

1

Latest round

Series D

Latest activity

May 2023